Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation

Executive Summary

The White House Waxman/Hatch reform proposal is unlikely to end the push for legislative changes to the generic drug approval process
Advertisement

Related Content

FDA Will Create “Limited” Rx Import System, Ex-CMS Head Predicts
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
Commissioner McClellan’s First FDA Appropriations Hearing, In Brief
DTC Ads Remain Controversial Despite Positive Study Results, PhRMA Says
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
Senate Change Puts Hatch, Gregg, Grassley In Line For Key Rx Committees
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation
Advertisement
UsernamePublicRestriction

Register

PS040675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel